Research analysts at Royal Bank Of Canada initiated coverage on shares of AveXis, Inc. (NASDAQ:AVXS) in a research note issued on Thursday, The Fly reports. The firm set a “sector perform” rating on the stock.

A number of other equities analysts also recently commented on the stock. Citigroup Inc. initiated coverage on shares of AveXis in a report on Tuesday, May 23rd. They set a “buy” rating and a $90.00 price objective for the company. Nomura initiated coverage on shares of AveXis in a report on Monday, August 28th. They set a “reduce” rating and a $52.00 price objective for the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $92.00 price objective on shares of AveXis in a report on Thursday, May 25th. Instinet initiated coverage on shares of AveXis in a report on Tuesday, August 29th. They set a “reduce” rating and a $52.00 price objective for the company. Finally, Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $99.75.

Shares of AveXis (AVXS) traded down 0.27% during midday trading on Thursday, hitting $89.75. 256,324 shares of the company were exchanged. The stock’s 50-day moving average is $93.16 and its 200-day moving average is $79.85. The stock’s market cap is $2.87 billion. AveXis has a one year low of $35.64 and a one year high of $99.45.

AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.10). During the same quarter in the previous year, the company earned ($0.68) EPS. Equities research analysts anticipate that AveXis will post ($6.04) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/14/royal-bank-of-canada-begins-coverage-on-avexis-inc-avxs.html.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $91.52, for a total value of $162,905.60. Following the completion of the sale, the vice president now owns 1,780 shares in the company, valued at approximately $162,905.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 5,340 shares of company stock valued at $474,637 in the last 90 days. Corporate insiders own 18.60% of the company’s stock.

Several large investors have recently modified their holdings of the company. Lord Abbett & CO. LLC acquired a new stake in shares of AveXis during the 2nd quarter worth approximately $20,614,000. Ameritas Investment Partners Inc. grew its position in shares of AveXis by 331.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after buying an additional 1,622 shares during the period. California State Teachers Retirement System grew its position in shares of AveXis by 280.6% during the 2nd quarter. California State Teachers Retirement System now owns 43,538 shares of the company’s stock worth $3,577,000 after buying an additional 32,100 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of AveXis by 210.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,961 shares of the company’s stock worth $1,312,000 after buying an additional 10,827 shares during the period. Finally, PointState Capital LP grew its position in shares of AveXis by 118.7% during the 2nd quarter. PointState Capital LP now owns 544,667 shares of the company’s stock worth $44,750,000 after buying an additional 295,600 shares during the period. Institutional investors own 94.71% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

The Fly

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.